Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, announced today that it has selected Bio-Connect BV to distribute the company’s products in The Netherlands, Belgium and Luxembourg.
“Bio-Connect BV is a dynamic company with excellent coverage of the life science research field, with a specialization in reagents,” said Ravi Vinayak, Ph.D., general manager of global channel distribution for Maravai LifeSciences. “Bio-Connect BV has an excellent network for distribution and support in the Benelux countries and we are now well positioned to meet the rapidly growing needs of the research community in Belgium, Netherlands and Luxembourg.”
Bio-Connect BV maintains three divisions: life sciences, diagnostics and services. The company focuses on offering competitive pricing, fast delivery and excellent customer service.
Cygnus Technologies develops, manufactures and markets assay kits and related services that enable pharmaceutical and biotech companies to detect and identify host cell impurities in biotherapeutics, an important step in regulatory approval and quality control processes. With products, services and expert advice, Cygnus helps biopharmaceutical companies move new therapeutics more quickly through the development and approval stages to market. With headquarters in Southport, N.C., Cygnus Technologies serves customers worldwide through a global distributor network. A privately held company, Cygnus Technologies was acquired by Maravai LifeSciences in 2016.
David Weber, Chief Commercial Officer